Jiangsu Hengrui Medicine Co., Ltd.
600276
Rang in aandelen
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aandeelprijs
$6.89
Marktkapitalisatie
$43.94B
Verandering (1 dag)
-2.91%
Verandering (1 jaar)
-24.78%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)
Categorie
Healthcare
P/B-ratio voor Jiangsu Hengrui Medicine Co., Ltd. (600276)
P/B-ratio op October 2026 TTM: 4.71
Volgens de meest recente financiële rapporten en aandelenkoers van Jiangsu Hengrui Medicine Co., Ltd. is de huidige P/B-ratio (TTM) 4.71. Eind 2024 had het bedrijf een P/B-ratio van 6.39.
P/B-ratiohistoriek voor Jiangsu Hengrui Medicine Co., Ltd. van 2001 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 4.71 | -25.48% |
| 2025 | 6.32 | -1.09% |
| 2024 | 6.39 | -9.65% |
| 2023 | 7.07 | 9.04% |
| 2022 | 6.49 | -29.84% |
| 2021 | 9.24 | -52.24% |
| 2020 | 19.35 | 24.50% |
| 2019 | 15.55 | 57.24% |
| 2018 | 9.89 | -5.23% |
| 2017 | 10.43 | 45.32% |
| 2016 | 7.18 | -10.85% |
| 2015 | 8.05 | 63.76% |
| 2014 | 4.92 | -13.09% |
| 2013 | 5.66 | 13.80% |
| 2012 | 4.97 | -8.81% |
| 2011 | 5.45 | -40.25% |
| 2010 | 9.12 | 4.84% |
| 2009 | 8.70 | 25.59% |
| 2008 | 6.93 | -35.14% |
| 2007 | 10.68 | 89.97% |
| 2006 | 5.62 | 451.70% |
| 2005 | 1.02 | 5.76% |
| 2004 | 0.96 | -9.87% |
| 2003 | 1.07 | -10.67% |
| 2002 | 1.20 | -6.19% |
| 2001 | 1.28 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 1.3124 | -72.13% |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 7.03% |
IN
|
